ENDRA Life Sciences Inc. (NDRA)

ENDRA Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	4.75	2.83	4.89	9.46	7.23	6.17
Cash & Short-Term Investments	4.75	2.83	4.89	9.46	7.23	6.17
Cash Growth	42.30%	-42.04%	-48.33%	30.91%	17.06%	-4.59%
Inventory	-	-	-	1.28	0.59	0.11
Prepaid Expenses	0.22	0.2	0.49	1.35	0.39	0.12
Other Current Assets	-	-	-	-	-	0.13
Total Current Assets	4.96	3.03	5.38	12.09	8.21	6.54
Property, Plant & Equipment	0.31	0.47	0.74	0.77	0.55	0.64
Other Long-Term Assets	3.11	3.26	3.15	0.01	0.01	-
Total Assets	8.38	6.75	9.27	12.87	8.76	7.18
Accounts Payable	0.63	0.36	0.61	0.79	0.4	1.28
Accrued Expenses	-	0.19	0.75	0.5	0.42	0.41
Short-Term Debt	-	0.15	0.16	0.12	0.08	0.32
Current Portion of Long-Term Debt	-	0.03	0.03	-	-	-
Current Portion of Leases	0.19	0.17	0.15	0.13	0.08	0.07
Total Current Liabilities	0.81	0.9	1.7	1.54	0.99	2.07
Long-Term Debt	-	-	-	0.03	0.34	-
Long-Term Leases	0.05	0.19	0.37	0.52	0.27	0.34
Other Long-Term Liabilities	0.91	-	-	-	-	-
Total Liabilities	1.77	1.1	2.07	2.09	1.6	2.42
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	105.89	97.58	89.07	79.46	64.49	49.93
Retained Earnings	-99.29	-91.93	-81.87	-68.69	-57.34	-45.22
Comprehensive Income & Other	0	0.01	0.01	0.01	0.01	0.04
Total Common Equity	6.6	5.66	7.2	10.78	7.17	4.76
Shareholders' Equity	6.6	5.66	7.2	10.78	7.17	4.76
Total Liabilities & Equity	8.38	6.75	9.27	12.87	8.76	7.18
Total Debt	0.24	0.54	0.71	0.8	0.77	0.73
Net Cash (Debt)	4.51	2.29	4.18	8.67	6.46	5.44
Net Cash Growth	67.86%	-45.24%	-51.72%	34.18%	18.64%	-15.59%
Working Capital	4.15	2.13	3.68	10.55	7.22	4.46
Tangible Book Value	6.6	5.66	7.2	10.78	7.17	4.76

Source: S&P Capital IQ. Standard template. Financial Sources.